Navigation Links
Pressure BioSciences, Inc. Issued First Patent in Canada
Date:8/30/2007

WEST BRIDGEWATER, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that it has been issued its first patent by the Canadian Intellectual Property Office. Entitled "Pressure-Mediated Binding of Biomolecular Complexes" (Number 2,259,318), this issuance extends the coverage of the Company's pressure cycling technology (PCT) patents previously issued in the United States, Japan, Germany, Italy, France, Sweden, Switzerland, and the U.K. The PCT methods covered by this patent relate to the association and disassociation of biomolecular complexes (such as antigen/antibody complexes) and the separation of biomolecules (such as proteins) from complex mixtures. Such methods may better enable the separation and purification of biomolecules (procedures that are performed routinely in pharmaceutical, biotechnology, and research laboratories) and may also improve the speed and sensitivity of both research and diagnostic tests, such as those used worldwide in the cancer, endocrine, and infectious diseases areas.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "We continue to focus our primary PCT efforts in the potentially large and rewarding area of sample preparation. We concomitantly look to add value by reviewing our extensive patent portfolio outside of sample preparation to determine if our PCT intellectual property may help others improve their efforts in the therapeutic, diagnostics, or research areas."

Schumacher continued: "The PCT methods covered by this patent have the potential to play a significant role in improving the speed, ease-of-use, and sensitivity of both diagnostic and research tests currently used in laboratories today. The addition of Canada to the list of countries in which patents with similar claims have already been issued adds measurably to the value of this exciting PCT application."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential of the Company's PCT in sample preparation and for other applications, the protection that issued patents may provide, and the size of the commercial markets for PCT applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the risk that the Company's products will not achieve market acceptance in the area of sample preparation or in other applications; the risk that the Company's issued patents, including the newly issued Canadian patent, may not prevent competitors from developing and selling competitive technology; the risk that, due to the technological developments of others, the Company may be unable to continue to extend its patent protection; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President

of Finance & CFO (508) 580-1818 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
2. Determination of N-nitrosamines in Baby Bottle Rubber Teats by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass Spectrometry
3. Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS
4. Medical College receives $11 million grant to study high blood pressure
5. Pressure mounts for Doyle to repeal shareholder liability law
6. Probe into gas gouging may educate Americans about pressures on oil supply
7. SWIB gets more pressure to invest in state tech start-ups
8. Technology puts pressure on old education methods
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. Midwest life science stocks sizzle in a tepid first quarter
11. Morgridge Institute for Research seeks first CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
Breaking Biology News(10 mins):